KUAISHOU-W
01024
XIAOMI-W
01810
JD HEALTH
06618
BILIBILI-W
09626
ALI HEALTH
00241
(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | 10.67%1.17B | 6.68%2.46B | -11.32%1.06B | 5.67%2.31B | 8.02%1.2B | 6.30%2.18B | 6.99%1.11B | 3.94%2.05B | 11.24%1.04B | 14.51%1.98B |
Operating income | 10.67%1.17B | 6.68%2.46B | -11.32%1.06B | 5.67%2.31B | 8.02%1.2B | 6.30%2.18B | 6.99%1.11B | 3.94%2.05B | 11.24%1.04B | 14.51%1.98B |
Operating expenses | ||||||||||
Gross profit | ||||||||||
Selling expenses | 10.42%-2.79M | -21.04%-6.12M | -29.10%-3.12M | -455.21%-5.06M | -2,470.21%-2.42M | 9.71%-911K | 89.86%-94K | 82.21%-1.01M | 66.24%-927K | -5.33%-5.67M |
Depreciation and amortization | -1.51%-399.08M | -1.18%-795.39M | 0.48%-393.14M | -2.68%-786.08M | -4.33%-395.03M | -13.16%-765.56M | -15.16%-378.65M | -10.93%-676.53M | -10.41%-328.79M | -12.31%-609.87M |
Impairment and provision | 2,645.26%171.25M | 99.31%-5.92M | 99.21%-6.73M | -521.72%-857.23M | -484.68%-856.49M | 9.23%-137.88M | -151.37%-146.49M | -513.78%-151.9M | -1,416.05%-58.28M | ---24.75M |
-Other impairment is provision | 2,645.26%171.25M | 99.31%-5.92M | 99.21%-6.73M | -521.72%-857.23M | -484.68%-856.49M | 9.23%-137.88M | -151.37%-146.49M | -513.78%-151.9M | -1,416.05%-58.28M | ---24.75M |
Special items of operating profit | -20.74%-67.05M | -14.41%-136.04M | -16.41%-55.53M | 20.69%-118.91M | -3.24%-47.7M | 15.81%-149.94M | 23.90%-46.2M | -64.84%-178.09M | -22.28%-60.72M | 6.66%-108.04M |
Operating profit | 45.51%876.31M | 181.19%1.52B | 670.87%602.24M | -52.19%539.77M | -119.68%-105.5M | 7.91%1.13B | -8.60%535.93M | -14.78%1.05B | 1.72%586.32M | 15.66%1.23B |
Financing cost | -19.61%-367.15M | -28.80%-657.24M | -27.17%-306.96M | -4.08%-510.28M | 2.79%-241.37M | -1.46%-490.28M | -6.75%-248.3M | -6.75%-483.24M | -3.46%-232.6M | -20.33%-452.7M |
Earning before tax | 72.43%509.16M | 2,817.54%860.56M | 185.13%295.28M | -95.38%29.5M | -220.60%-346.87M | 13.44%638.67M | -18.69%287.62M | -27.35%563M | 0.61%353.72M | 13.09%774.93M |
Tax | -45.78%-49.16M | -924.32%-96.66M | -198.26%-33.72M | 87.80%-9.44M | 201.84%34.32M | -45.50%-77.35M | -10.90%-33.7M | 26.84%-53.16M | 0.35%-30.38M | -12.16%-72.67M |
After-tax profit from continuing operations | 75.87%460M | 3,708.09%763.9M | 183.68%261.56M | -96.43%20.06M | -223.09%-312.55M | 10.10%561.32M | -21.47%253.93M | -27.40%509.84M | 0.70%323.33M | 13.19%702.26M |
Earning after tax | 75.87%460M | 3,708.09%763.9M | 183.68%261.56M | -96.43%20.06M | -223.09%-312.55M | 10.10%561.32M | -21.47%253.93M | -27.40%509.84M | 0.70%323.33M | 13.19%702.26M |
Profit attributable to shareholders | 75.87%460M | 3,708.09%763.9M | 183.68%261.56M | -96.43%20.06M | -223.09%-312.55M | 10.10%561.32M | -21.47%253.93M | -27.40%509.84M | 0.70%323.33M | 13.19%702.26M |
Basic earnings per share | 73.68%0.66 | 3,566.67%1.1 | 184.44%0.38 | -96.30%0.03 | -221.62%-0.45 | 10.96%0.81 | -21.28%0.37 | -27.72%0.73 | 2.17%0.47 | 13.48%1.01 |
Diluted earnings per share | 73.68%0.66 | 3,566.67%1.1 | 184.44%0.38 | -96.30%0.03 | -221.62%-0.45 | 10.96%0.81 | -21.28%0.37 | -27.72%0.73 | 2.17%0.47 | 13.48%1.01 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
Auditor | -- | PricewaterhouseCoopers LLP | -- | PricewaterhouseCoopers LLP | -- | PricewaterhouseCoopers LLP | -- | Ernst & Young LLP | -- | Ernst & Young LLP |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.